Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

The primary results report of NCT01492361. Its numbers are set against the trial’s posted results below.

What the trial testedrandomised · 8,179 people · 2019

Randomised comparison

−20%−34% to −2%

17 in 100 instead of 22

Bigger than 4 in 10 for cardiovascular events

As reported

HR 0.80, 95% CI 0.66–0.98

Same as the trial’s posted resultThis paper HR 0.75 (0.68–0.83)Posted, primary outcome HR 0.75 (0.68–0.83), p = 0.00000001Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization.
Same as the trial’s posted resultThis paper HR 0.80 (0.66–0.98)Posted HR 0.80 (0.66–0.98), p = 0.0315CV Death.
Same as the trial’s posted resultThis paper HR 0.74 (0.65–0.83)Posted HR 0.74 (0.65–0.83), p = 0.0000006Composite of CV Death, Nonfatal MI (Including Silent MI), or Nonfatal Stroke.

the abstract, start to end

… death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03).

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

HR 0.800.66–0.98

Other lipid agentsCardiovascular events

Other lipid agents × cardiovascular eventshelps?settled

unlikelylikely

0.800.50 without it

← favours treatmentfavours comparator →

more certainless certain

1 / 5

2019

…

2025

2026

this paperpooled ittrialcites it